Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma

New therapies, including the anti‐cytotoxic T lymphocyte antigen (CTLA)‐4 antibody, ipilimumab, is approved for metastatic melanoma. Prognostic biomarkers need to be identified, because the treatment has serious side effects. Serum samples were obtained before and during treatment from 56 patients w...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Exp Immunol
Auteurs principaux: Nyakas, M., Aamdal, E., Jacobsen, K. D., Guren, T. K., Aamdal, S., Hagene, K. T., Brunsvig, P., Yndestad, A., Halvorsen, B., Tasken, K. A., Aukrust, P., Mælandsmo, G. M., Ueland, T.
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2019
Sujets:
Original Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6591141/
https://ncbi.nlm.nih.gov/pubmed/30821848
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cei.13283
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires